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Abstract: Background: Trimethylamine-N-oxide (TMAO), a choline-derived gut microbiota-dependent
metabolite, is a newly recognized risk marker for cardiovascular disease. We sought to determine:
(1) TMAO response to meals containing free versus lipid-soluble choline and (2) effects of gut
microbiome on TMAO response. Methods: In a randomized, controlled, double-blinded, crossover
study, healthy men (n = 37) were provided meals containing 600 mg choline either as choline bitartrate
or phosphatidylcholine, or no choline control. Results: Choline bitartrate yielded three-times greater
plasma TMAO AUC (p = 0.01) and 2.5-times greater urinary TMAO change from baseline (p = 0.01)
compared to no choline and phosphatidylcholine. Gut microbiota composition differed (permutational
multivariate analysis of variance, PERMANOVA; p = 0.01) between high-TMAO producers (with
≥40% increase in urinary TMAO response to choline bitartrate) and low-TMAO producers (with <40%
increase in TMAO response). High-TMAO producers had more abundant lineages of Clostridium from
Ruminococcaceae and Lachnospiraceae compared to low-TMAO producers (analysis of composition of
microbiomes, ANCOM; p < 0.05). Conclusion: Given that phosphatidylcholine is the major form
of choline in food, the absence of TMAO elevation with phosphatidylcholine counters arguments
that phosphatidylcholine should be avoided due to TMAO-producing characteristics. Further,
development of individualized dietary recommendations based on the gut microbiome may be
effective in reducing disease risk
Keywords: dietary precursor intake; choline; gut microbiota; metabolism; trimethylamine-N-oxide
1. Introduction
Choline serves as a dietary precursor for the gut microbial-generated trimethylamine (TMA) that
is subsequently oxidized by the hepatic enzyme flavin-containing monooxygenase 3 (FMO3) to form
trimethylamine-N-oxide (TMAO), a newly recognized risk marker for cardiovascular disease [1,2].
Choline is present as free and lipid-soluble forms (mainly as phosphatidylcholine), with food products
consisting of various forms of choline [3]. Free choline is absorbed in the small intestine by
sodium-independent carrier mediated transport [4]. In contrast, phosphatidylcholine is mainly
hydrolyzed to lysophosphatidylcholine by the action of pancreatic phospholipase A2 IB and jejunoileal
brush-border phospholipase B, with a portion reacylated to phosphatidylcholine for incorporation
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into chylomicrons and the remainder further hydrolyzed to glycerophosphocholine (subsequently to
glycerophosphate and free choline) [4]. These differences in absorption suggest that free choline, but
not phosphatidylcholine, may be a more readily available substrate for gut microbes to form TMA.
Consistent with this, free choline, but not phosphatidylcholine, has been shown to yield high urinary
TMA excretion in healthy volunteers [5] and fishy odor (from over-production of TMA) in patients
with Huntington’s disease [6]. However, recent studies have reported greater TMAO concentrations
with the ingestion of ≥2 eggs (consumption of mostly phosphatidylcholine) [1,7], making unclear the
contribution of different forms of choline on TMAO production. Further, considerable interindividual
variations were found in circulating and urinary TMAO response to supplemental choline [8] and
egg ingestion [7,9], but limited attention has been given to the relationship between underlying gut
microbiota differences between individuals and TMAO production.
Therefore, we compared acute TMAO response to meals containing supplemental choline bitartrate
versus phosphatidylcholine (choline bitartrate and phosphatidylcholine being two of several applicable
choline-delivering compounds) and determined whether differences in TMAO response arise due to
the gut microbiota differences between individuals. We have previously reported that individuals
with a greater ratio of the gut microbial phyla Firmicutes to Bacteroidetes and a less diverse gut
microbiota exhibited higher TMAO response to egg ingestion [9]. In the following randomized,
controlled, double-blinded, crossover study comparing choline bitartrate and phosphatidylcholine, we
hypothesized that choline bitartrate would elevate TMAO response more than phosphatidylcholine, and
that this response would be modified by gut microbiota composition. Because a greater enrichment of
Firmicutes versus Bacteroidetes has been associated with obesity [10], our original study design included
both obese and normal-weight individuals to explore differences in gut microbiota composition as a
primary determinant of TMAO levels.
2. Materials and Methods
2.1. Subjects
Forty-one (37 men and 4 non-pregnant/non-lactating women) healthy individuals aged 21–50 years
completed the study, consisting of 29 individuals (25 men and 4 women) with a BMI of 20–24.9 kg/m2 and
12 individuals (12 men and no women) with a BMI of 30–39.9 kg/m2. Three individuals (1 normal-weight
male, 1 normal-weight female and 1 obese male) were unable to complete the study due to a scheduling
conflict. They were recruited through fliers posted on the campus of Utah State University from
November 2017 to May 2018. The exclusion criteria were age > 50 y, BMI < 20, 25–29.9 or ≥40 kg/m2,
pregnant or planning to become pregnant during the course of the study (women), vegetarians, smokers
or recreational drug users, individuals with gastrointestinal diseases or complaints, chronic illnesses or
other metabolic diseases (including trimethylaminuria), abnormal blood chemistry or blood cell count
values indicative of organ dysfunctions, subjects who have taken antibiotics within the past 2 months
and those who are unwilling to discontinue pre- and probiotics and dietary supplements for the time
leading up to two months before and during the study. Written informed consent was obtained from
all participants prior to study enrollment. Figure 1A shows a schematic of the participant flow.
Clinical Trials Registry: NCT04255368 at https://clinicaltrials.gov/ct2/show/NCT04255368?term=
NCT04255368&draw=2&rank=1.
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Figure 1. A schematic of the participant flow (A) and the study protocol (B). 
Given difficulty in recruiting obese individuals and women, a revised post hoc calculation was 
performed based on the achieved sample number and the assumed within-subject coefficient of 
variations of 20% for plasma TMAO concentrations based on our prior study [9] with duplicate 
measures at the end of each intervention; α < 0.05 for 2-sided tests and using no corrections for 
multiple testing. The sample size of 37 participants provided an 80% probability of detecting a 
difference in TMAO of 10%, and additionally assumed a 10% study drop-out rate. The study was 
approved by the Institutional Review Board at Utah State University (Protocol ID#: 8547). This trial 
was registered at clinicaltrials.gov as NCT04255368. 
2.2. Design 
The study design was a randomized, controlled, double-blinded, crossover dietary intervention 
that provided meals containing 600 mg choline either as choline bitartrate (Balchem, New Hampton, 
NY, USA; choline bitartrate consisting of 41% choline) or phosphatidylcholine (American Lecithin 
Company, Oxford, CT, USA; Alcolec 40P consisting of 40% phosphatidylcholine), or no choline 
control. Both choline bitartrate and phosphatidylcholine were in the form of odorless powder and 
were adjusted to provide 600 mg choline (choline bitartrate provided ~40% choline by weight; 
phosphatidylcholine derived from soybean provided ~15% choline by weight). The study meals were 
prepared by mixing 118 mL of condensed tomato soup with water to a total volume of 237 mL, 
heating in a commercial microwave for 2.5 min on high and cooled for 1 min to a serving temperature 
at 55–58 °C, then adding the respective choline-containing powders.  
The order of three study meals was determined by a study investigator using a random number 
generator (random.org), and the participants were randomized to one of six meal sequences A 
through F. Approximately the same number of participants were assigned to each of the six meal 
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Institutional Review Board at Utah State University (Protocol ID#: 8547). This trial was registered at
clinicaltrials.gov as NCT04255368.
2.2. Design
The study design was a ra i , ll , l li , r ss er dietary intervention
that provided meals containing 6 li it r li itartrate (Balchem, New Hampton,
NY, USA; choline bitartrate consisting of 41 choli e) r s ti lc li e ( erican Lecithin
Company, Oxford, CT, USA; lcolec 40P consisting of 40% phosphatidylcholine), or no choline control.
Both choline bitartrate and phosphatidylcholine were in the form of odorless powder and were adjusted
to provide 600 mg choline (choline bitartrate provided ~40% choline by weight; phosphatidylcholine
derived from soybean provided ~15% choline by weight). The study meals were prepared by mixing
118 mL of condensed tomato soup with water to a total volume of 237 mL, heating in a commercial
microwave for 2.5 min on high and cooled for 1 min to a serving temperature at 55–58 ◦C, then adding
the respective choline-containing powders.
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The order of three study meals was determined by a study investigator using a random number
generator (random.org), and the participants were randomized to one of six meal sequences A through
F. Approximately the same number of participants were assigned to each of the six meal sequences (out
of the 37 participants, n = 5 for sequences A and C, n = 6 for sequence B and n = 7 for sequences D–F).
Each meal was administered in a single day separated by a one-week washout period. Participants as
well as study personnel who interacted with participants or analyzed the samples were not provided
with information linking the study meal order and content (i.e., double-blinded). All meals were
prepared in the Center for Human Nutrition Studies Clinic kitchen at Utah State University on the
morning of testing.
2.3. Protocol
After a 10-h overnight fast, participants arrived at the Center for Human Nutrition Studies Clinic
at Utah State University between 0700–1000 for each of the three visits. The day prior to the session,
participants were advised to avoid consumption of grapefruit juice and indole-containing vegetables
(e.g., broccoli, brussels sprouts, cabbage) [11] and fish [9] as they influence FMO3 activity and/or TMAO
response. A 24-h food diary was used to assess compliance to the grapefruit juice, indole food and fish
restriction. A baseline blood sample was obtained by a phlebotomist using a standard venipuncture
procedure and participants collected their baseline urine. Participants were also asked to submit a
one-time baseline stool sample. Participants were provided with a meal consisting of one cup (237 mL)
of tomato soup containing randomly allocated choline bitartrate, phosphatidylcholine or no choline
control, a bagel with margarine-butter spread and one cup of water. Meals were consumed within a
15-min period. Following the study meal consumption, serial blood was obtained at 30 min, and 1,
2, 4 and 6 h, and each participant collected their urine sample throughout the 6-h study period; this
timeframe was based on our previous studies demonstrating that 6 h were sufficient to capture the times
where the change in TMAO was the greatest and reached steady state [12]. At 4.5 h, participants were
provided with a fixed snack (i.e., apple sauce) and water. Throughout each study session, participants
refrained from eating and drinking foods and beverages (other than water) outside those provided by
study personnel. The study protocol is shown in Figure 1B.
2.4. Sample Collection
2.4.1. Serum and Whole Blood
At the screening visit, whole blood was collected in serum separator and EDTA-coated tubes
(Becton, Dickinson and Company, Franklin Lakes, NJ, USA) for blood chemistry profile and complete
blood count, respectively.
2.4.2. Plasma and Buffy Coat
For each study session, whole blood was collected in EDTA-coated tubes, placed on ice immediately
and centrifuged at 2000× g at 4 ◦C for 10 min. Plasma was aliquoted into screw-top cryogenic vials and
stored at −80 ◦C for further metabolite analyses. Buffy coat was aliquoted into screw-top cryogenic
vials (Thermo Fisher Scientific, Waltham, MA, USA) with 50 µL DMSO, gently mixed by inversion and
stored at −80 ◦C for genotyping of the flavin-containing monooxygenase isoform 3 (FMO3 G472A rs
2266782; E158K) genetic variant known to influence TMA conversion.
2.4.3. Urine
At study baseline, spot urine was self-collected in wide-mouth specimen containers (120 mL;
Thermo Fisher Scientific). In addition, 6-h urine was self-collected in wide-mouth polyethylene bottles
(1 L; Thermo Fisher Scientific) throughout the study period. The total urine volume was recorded for
study baseline and the 6-h study period. Urine was kept on ice prior to aliquoting into screw-top
cryogenic vials for storage at −80 ◦C for further metabolite analyses.
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2.4.4. Stool
A ~40 g stool sample from a single bowel movement was self-collected using a stool collection kit
containing a specimen receptacle, disposable sterile spoon, sterile conical tubes (BD) and disposable
exam gloves. Participants delivered their stool samples in a thermo-insulated bag with ice packs to the
Center for Human Nutrition Studies Clinic. Stool samples were aliquoted and stored at −80 ◦C for
further gut microbiome analyses.
2.4.5. Study Meal Homogenate
Each study meal was homogenized in a commercial blender, aliquoted into storage tubes and
stored at −80 ◦C for metabolite analyses.
2.5. Analytical Methodology
2.5.1. Screening Blood Chemistry and Complete Cell Counts
Serum concentrations of fasting glucose, blood urea nitrogen (BUN), creatinine (Cr), total
bilirubin, total protein, alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine
aminotransferase (ALT), as well as complete blood cell counts of red blood cells, white blood cells,
lymphocytes, monocytes and neutrophils, were measured from blood collected at screening (LabCorp,
Phoenix, AZ, USA). The estimated glomerular filtrate rate (eGFR) was calculated using the Chronic
Kidney Disease Epidemiology Collaboration equation [13].
2.5.2. TMAO and Choline Measurements in Study Meal, Plasma and Urine
TMAO and choline were measured in study food, plasma and urine samples by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) as previously described [9,14] with
modifications from [15]. Urinary metabolite concentrations were adjusted for creatinine, which
was measured using a Creatinine (urinary) Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI,
USA) according to the manufacturer’s specifications. Study meal total choline (sum of free choline,
glycerophosphocholine, phosphocholine, phosphatidylcholine, sphingomyelin) and betaine contents
were quantified [16,17] with modifications [18]. The system consisted of a TSQ Quantum Ultra mass
spectrometer with electrospray ionization source equipped with a refrigerated Accela autosampler
and an Accela pump with degasser (Thermo Fisher Scientific). Samples were run in batches with each
batch containing all time points and study meals, with an equal number of samples from each study
meal group.
2.5.3. 16S rRNA Gene Sequencing
Genomic DNA was extracted from ~100 mg of stool using the QIAmp Fast DNA Stool
Mini Kit (Qiagen, Valencia, CA, USA) with bead beating according to the manufacturer’s
specifications. The DNA concentration was quantified using the NanoQuant Plate spectrophotometer
(Tecan, Männedorf, Switzerland) and normalized to a concentration of 5 ng/µL, and the
DNA quality was assessed on a 1.5% agarose gel. The V4 hypervariable region of the
bacterial 16S rRNA gene was polymerase chain reaction (PCR) amplified and sequenced
with the 16S-specific primers fused to the standard Illumina sequencing adaptor sequences
(515F 5′-ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGYCAGCMGCCGCGGTAA-3′ and
806R 5′-GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGGACTACNV GGGTWTCTAAT-3′; the
italicized sequences are the Illumina sequences and the underlined sequences are the conserved
bacterial primers 515F and 806R, respectively) followed by a second PCR reaction with the indexing
primers as outlined in the Illumina 16S Metagenomic Sequencing Library Preparation guide [19]
using the dual-index strategy [20]. All primers were purchased from Integrated DNA Technologies
as 100 nmol standard desalted oligonucleotides. PCR reactions were performed in triplicates that
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consisted of Master Mix Platinum Hot Start (Thermo Fisher Scientific), 5 ng DNA template and 200 nM
of each primer, with initial denaturation at 94 ◦C for 3 min followed by 35 cycles of denaturation at
94 ◦C for 45 s, annealing at 50 ◦C for 60 s, extension at 72 ◦C for 60 s and final extension at 72 ◦C for
10 min. After thermocycling, triplicate reactions were combined and diluted 50-fold. Indexes were
then added in a PCR reaction that consisted of Master Mix Platinum Hot Start (Thermo Fisher), 400 nM
of p5 indexing primer and 400 nM of p7 indexing primer, with initial denaturation at 94 ◦C for 1 min
followed by 10 cycles of denaturation at 94 ◦C for 15 s, annealing at 64 ◦C for 15 s, extension at 72 ◦C
for 60 s and final extension at 72 ◦C for 3 min. PCR products were purified using Agencourt AMPure
beads (Beckman Coulter, Indianapolis, IN, USA) and were quantified using the Quant-iT PicoGreen
dsDNA Assay Kit (Invitrogen – Molecular Probes, Eugene, OR, USA). Purified PCR products were
diluted to a final concentration of 1 ng/µL, pooled in equal amounts and sequenced on an Illumina
MiSeq instrument with the MiSeq Reagent Kit V2 (500 cycle; 2 × 250 bp paired-end reads) at the Center
for Integrated Biosystems at Utah State University.
Demultiplexed paired-end reads were imported to the Quantitative Insights Into Microbial
Ecology (QIIME2) version 2019.7 and quality-controlled with the DADA2 package [21] truncating
forward and reverse reads to 240 and 230 base pairs, respectively, which removed sequences that
contained Q scores below 30. The amplicon sequence variants were assigned taxonomy using the
taxonomic classifier trained on the 515F/806R region of the Greengenes 13_8 database reference
sequences [22] clustered at 99% sequence similarity. A multiple-sequence alignment was generated
using MAFFT [23] and a phylogenetic tree was constructed using FastTree and midpoint-root. Core
metric analyses were performed using the q2-diversity plugin with rarefication to a sampling depth of
29,000. Alpha-diversity measures included Faith’s phylogenetic diversity and Shannon’s diversity
index. Beta-diversity measures included unweighted UniFrac distances. Principal coordinates analysis
(PCoA) plot was generated using Emperor [24] from unweighted UniFrac distances [25].
2.5.4. FMO3 Genotype
DNA was extracted from buffy coat collected at baseline using the DNeasy Tissue kit (Qiagen)
according to the manufacturer’s protocol. The most common variant FMO3 G472A (rs 2266782;
E158K) known to influence N-oxygenation of TMA [26] was determined for each participant using a
commercially available fluorescent Taqman endpoint SNP genotyping assay kit (Thermo Scientific) on
the QuantStudio 12K Flex System (Applied Biosystems, Foster City, CA, USA). A reaction plate was
created with 20 ng of dried-down genomic DNA on the 384-well optical reaction plate with initiation
at 95 ◦C for 5 min followed by 45 cycles of denaturation at 95 ◦C for 15 s and annealing/extension at
60 ◦C for 60 s. A pre-read and post-PCR read were performed at 60 ◦C on the plate. Samples were run
in duplicate reactions with 2 in-run standards and 6 negative water controls.
2.6. Statistical Analyses
Statistical analyses were conducted in SAS Version 9.3 (SAS Institute, Cary, NC, USA). Two-way
repeated measures analysis of variance (ANOVA) using the PROC MIXED model procedure was
performed to determine the effect of study meal, time and study meal-by-time interaction on metabolite
concentration change from baseline. When a meal-and-time interaction was statistically significant,
one-way ANOVA using the PROC MIXED model procedure was followed by the Tukey-Kramer
post hoc test to determine the effect of study meal at each time of measurement. The incremental
area under the curve (iAUC) was calculated for plasma TMAO response to study meal consumption
across the 6-h study period. Participants were categorized as high-TMAO producers or low-TMAO
producers based on the median excretion of TMAO (40%) in response to choline bitartrate consumption.
Age, BMI, study session order and genotype FMO3 G472A known to influence the conversion from
trimethylamine to TMAO [27] were included in the initial statistical model. Variables that did not
reach a significance of p ≤ 0.1 were removed to preserve degrees of freedom.
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Group significance for alpha-diversity and beta-diversity was assessed with Kruskal-Wallis and
permutational multivariate analysis of variance (PERMANOVA) statistical framework using the Adonis
function (999 permutations) in the vegan package of R [28], respectively. The analysis of composition of
microbiomes (ANCOM) statistical framework [29] was used to identify taxa that are present in different
abundances in high-versus low-TMAO producers at genus level. The W-value generated by ANCOM
is a count of a number of sub-hypotheses that were detected to be significantly different across tested
groups for a given taxon. Multiple hypothesis testing was corrected by the Benjamini-Hochberg False
Discovery Rate (FDR) correction at 5%. Significant differences were reported at p < 0.05. All data are
expressed as means ± SEM.
3. Results
3.1. Participant Characteristics
Thirty-seven men participated in this study, of whom were 25 normal-weight men (with mean
age of 25.3 ± 0.6 years, BMI of 23.3 ± 0.3 kg/m2) and 12 obese men (with mean age of 28.3 ± 2.0 years,
BMI of 32.8 ± 0.7 kg/m2) as shown in Table 1. Due to the insufficient sample size of women (with only
4 normal-weight women) and obese individuals (12 obese men versus 25 normal-weight men), our
final analyses pooled 37 men (25 normal-weight and 12 obese men together) to explore the role of gut
microbiota composition in variations of TMAO response, thus our results are preliminary. Serum blood
chemistry and blood cell counts were within the normal range. Fifty-one percent of the participants
were homozygous wild-type GG genotype for FMO3 G472A, 32% were heterozygous GA and 16%
were homozygous variant AA (normal-weight: 48% GG, 36% GA and 16% AA; obese: 58% GG, 25%
GA and 17% AA), whereby the percentage of participants with the variant genotypes resembled the
approximate distribution observed in the general population [30].
Table 1. Participant characteristics for normal-weight (n = 25) and obese (n = 12) participants.
Participant Characteristics Normal-Weight (n = 25) Obese (n = 12)
Age y 25.3 ± 0.6 28.3 ± 2.0
BMI kg/m2 23.3 ± 0.3 32.8 ± 0.7
Genotype
FMO3 G472A
rs 226678
GG% 48 58
GA% 36 25
AA% 16 17
Serum Blood Chemistry
Glucose mg/dL 87 ± 1 90 ± 2
BUN mg/dL 16 ± 1 15 ± 1
Cr mg/dL 1.0 ± 0.0 0.9 ± 0.0
Total bilirubin mg/dL 0.9 ± 0.1 0.9 ± 0.3
Total protein g/dL 7.1 ± 0.1 7.3 ± 0.3
ALP IU/L 68 ± 3 74 ± 5
AST IU/L 21 ± 1 23 ± 1
ALT IU/L 21 ± 1 26 ± 2
eGFR mL/min/1.73 m2 106 ± 3 109 ± 4
Blood Cell Counts
RBC ×106/µL 5.2 ± 0.1 5.4 ± 0.1
WBC ×103/µL 5.9 ± 0.4 6.9 ± 0.4
Lymphocytes ×103/µL 1.9 ± 0.1 2.3 ± 0.2
Monocytes ×103/µL 0.5 ± 0.0 0.6 ± 0.0
Neutrophils ×103/µL 3.2 ± 0.3 3.5 ± 0.3
Abbreviations: BMI, body mass index; FMO3, flavin-containing monooxygenase isoform 3; BUN, blood urea
nitrogen; Cr, creatinine; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase;
eGFR, estimated glomerular filtration rate; RBC, red blood cell; and WBC, white blood cell. Values are mean ± SEM.
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3.2. Food Choline, Betaine and TMAO Content
The study meals consisted of 1 cup (237 mL) of tomato soup containing different forms of choline
and provided approximately 600 mg of choline as choline bitartrate or phosphatidylcholine, compared
to no choline control. Table 2 shows food choline, betaine and TMAO content, with total choline content
calculated as the sum of free choline, glycerophosphocholine, phosphocholine, phosphatidylcholine,
and sphingomyelin. The choline bitartrate meal had 619 mg total choline of which 590 mg was free
choline and 14 mg phosphatidylcholine. The phosphatidylcholine meal had 623 mg total choline of
which 19 mg was free choline and 588 mg phosphatidylcholine. A control meal with no choline added
had 42 mg total choline of which 17 mg was free choline and 11 mg phosphatidylcholine. All study
meals had the same betaine content of 7 mg. No TMAO was detected in all three meals.
Table 2. Food amount and metabolite content of trimethylamine-N-oxide (TMAO), total choline, free
choline, phosphatidylcholine and betaine in tomato soup containing (i) 600 mg choline as choline
bitartrate; (ii) 600 mg choline as phosphatidylcholine; or (iii) no choline control.
Tomato Soup with
No Choline
Tomato Soup with
600 mg Choline as
Choline Bitartrate
Tomato Soup with
600 mg Choline as
Phosphatidylcholine
Food Amount mL 237 237 237
Food metabolite content
TMAO mg ND ND ND
Total choline 1 mg 42 619 623
Free choline mg 17 590 19
Phosphatidylcholine mg 11 14 588
Betaine mg 7 7 7
1 Total choline amount was calculated as the sum of free choline, glycerophosphocholine, phosphocholine,
phosphatidylcholine, and sphingomyelin. ND denotes not detectable. Values are shown as mean with each meal
run in triplicates with the intraassay CV: 2% for free choline, 7% for phosphatidylcholine and 3% betaine.
3.3. TMAO Response to Choline Bitartrate and Phosphatidylcholine
Fasting TMAO concentrations in plasma and urine at 0 min study-baseline were not different
across the study meals. Study meal choline form significantly affected post-meal increases in plasma
TMAO change from 0 min study-baseline (meal x time; p = 0.0002) as shown in Figure 2. Compared
to phosphatidylcholine and no choline control, choline bitartrate yielded three-times higher plasma
TMAO AUC (p = 0.01; Figure 3) and 4.4-times higher plasma TMAO maximum increase from baseline
(p < 0.0001; Figure 2).
In contrast, phosphatidylcholine did not differ in TMAO increase from baseline throughout the
6-h study period compared to no choline control. Similar to plasma TMAO change, choline bitartrate
resulted in 2.5-times higher urinary TMAO change from 0 min study-baseline (p = 0.01) compared to
phosphatidylcholine and no choline control, with no difference between phosphatidylcholine and no
choline as shown in Table 3.
Table 3. Effects of the study meals on urinary concentrations of trimethylamine-N-oxide (TMAO) and
choline adjusted for creatinine (Cr) change from 0 min study-baseline. One-way ANOVA, Tukey-Kramer
post hoc test showed a significant effect of study meal for TMAO and choline change from baseline as
indicated by different letter superscripts. Values are mean ± SEM, n = 37 per study meal.
(nmol/mmol Cr in Urine) No Choline CholineBitartrate Phosphatidylcholine p Value
TMAO 2.3 ± 1.4 a 9.6 ± 2.2 b 2.9 ± 1.7 a p = 0.01
Free choline 0.5 ± 0.1 a 1.3 ± 0.2 b 0.9 ± 0.1 b p = 0.0005
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Figure 3. Plasma trimethylamine-N-oxide (TMAO) response to study meal consumption as incremental
area under the curve (iAUC) across the 6-h study period. Different letter superscripts show a significant
effect of study meal (one-way ANOVA, Tukey-Kramer post hoc test; p = 0.01). Values are mean ± SEM,
n = 37 per study meal.
The individual variations in urinary TMAO change from 0 min study-baseline after choline
bitartrate consumption ranged from −80% to 1400% as shown in Figure 4. Forty percent increase was
chosen as the median to stratify our participants into high-TMAO producers (n = 17; those with ≥40%
urinary TMAO increase from 0 min study-baseline in response to choline bitartrate) versus low-TMAO
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producers (n = 17; those with <40% urinary TMAO increase from 0 min study-baseline in response to
choline bitartrate). This value was chosen prior to the gut microbiome analyses, which retained 34
samples after rarefication to a sampling depth of 29,000 (see Section 3.5 on Gut Microbiota Composition).
Nutrients 2020, 12, x FOR PEER REVIEW 10 of 19 
 
urinary TMAO increase from 0 min study-baseline in response to choline bitartrate) versus low-
TMAO producers (n = 17; those with <40% urinary TMAO increase from 0 min study-baseline in 
response to choline bitartrate). This value was chosen prior to the gut microbiome analyses, which 
retained 34 samples after rarefication to a sampling depth of 29,000 (see Section 3.5 on Gut Microbiota 
Composition). 
 
Figure 4. Percentage change in urinary trimethylamine-N-oxide (TMAO) concentrations following 
choline bitartrate consumption shown in rank-order of response. The percentage change ranged from 
−80% to 1400% among participants. The median value of 40% was used as a cutoff to stratify the 
participants into high-TMAO producers (n = 17; those with ≥40% urinary TMAO increase from 0 min 
study-baseline in response to choline bitartrate) and low-TMAO producers (n = 17; those with <40% 
urinary TMAO increase from 0 min study-baseline in response to choline bitartrate) were compared 
for the gut microbiome analyses. 
3.4. Choline Response to Choline Bitartrate and Phosphatidylcholine 
Fasting choline concentrations in plasma and urine at 0 min study-baseline were not different 
across the study meals. Choline form significantly influenced post-meal increases in plasma choline 
change from 0 min study-baseline (meal × time; p < 0.0001) as shown in Figure 5. Plasma free choline 
increase from 1–2 h was highest with choline bitartrate consumption (3.4-times greater) followed by 
phosphatidylcholine (2.4 times greater) compared to no choline control (p < 0.0001). At 6-h, plasma 
choline increase was 3.1-times greater only with phosphatidylcholine (p < 0.0001) with no differences 
between no choline control and choline bitartrate (Figure 5). Plasma free choline concentration 
peaked 1-h after choline bitartrate consumption and declined from 2–6 h reaching a level not different 
to that of no choline control at 6-h. The trajectory over time differed for phosphatidylcholine where 
plasma free choline concentration was not as high as that of choline bitartrate at the earlier time points 
but remained elevated throughout the study period, being greater than choline bitartrate and no 
Figure 4. Percentage change in ri ary tri et yla ine-N-oxide (T AO) concentrations fo lowing
choline bitartrate consumption shown in rank-order of response. The percentage change ranged from
−80% to 14 0% among participants. The median value of 40% was used as a cutoff to stratify the
participants into high-T pr c rs ( 17; those with ≥40% urinary TMAO increase from 0 min
study-baseline in response to choline bitartrate) and lo -T pro cers ( 17; those ith 40%
urinary T i in study-baseline in response to choline bitart ate) wer compared for
the gut microbi me analyses.
3.4. Choline Response to Choline Bitartrate and Phosphatidylcholine
Fasting choline concentrations in plasma and urine at 0 min study-baseline were not different
across the study meals. Choline form significantly influenced post-meal increases in plasma choline
change from 0 min study-baseline (meal × time; p < 0.0001) as shown in Figure 5. Plasma free choline
increase from 1–2 h was highest with choline bitartrate consumption (3.4-times greater) followed by
phosphatidylcholine (2.4 times greater) compared to no choline control (p < 0.0001). At 6-h, plasma
choline increase was 3.1-times greater only with phosphatidylcholine (p < 0.0001) with no differences
between no choline control and choline bitartrate (Figure 5). Plasma free choline concentration peaked
1-h after choline bitartrate consumption and declined from 2–6 h reaching a level not different to that
of no choline control at 6-h. The trajectory over time differed for phosphatidylcholine where plasma
free choline concentration was not as high as that of choline bitartrate at the earlier time points but
remained elevated throughout the study period, being greater than choline bitartrate and no choline
groups at 6-h. Similar to plasma choline change, urinary choline change from study-baseline was
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1.2-times higher after choline bitartrate and phosphatidylcholine consumption (p = 0.0005) compared
to no choline control as shown in Table 3.
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Figure 5. Effects of the study meals on plasma free choline change from 0 min study-baseline across the
6-h study period. Different letter superscripts show a significant effect of study meal at each time point
determined by one-way ANOVA, Tukey-Kramer post hoc test. Values are mean ± SEM, n = 37 per
study meal.
3.5. Gut Microbiota Composition
Demultiplexing and DADA2 package within QIIME2 yielded a total of 7,590,141 high-quality
gene sequences with mean sequence lengths of 292 ± 8 (mean ± standard deviation). Of the 37 samples,
rarefication to a sampling d pth of 29,000 retained 34 sample , which were used for down tream
analyses. High-TMAO pro ucers (n = 17; those with ≥40% urinary TMAO increase fr m 0 min
study-ba eline in response to choline bitar rate) and low-TMAO producers (n = 17; those with <40%
urinary TMAO incr ase fr m 0 min study-baseline in response to choline bitartrate) were compared
for the gut microbio e analyses.
Alpha-diversity (within-individual) measures were not different between high- versus low-TMAO
producers (data not sho n). High-TMAO producers had significantly differen b ta-diversity measures
using the unweighted U iFrac distances (PERMANOVA p = 0.01, R2 = 0.05 with 999 permutations
using th Ado is function) compared to low-TMAO producers as shown in Figure 6.
Nutrients 2020, 12, 2220 12 of 20Nutrients 2020, 12, x FOR PEER REVIEW 12 of 19 
 
 
Figure 6. Principal coordinates analysis (PCoA) plot of the unweighted UniFrac distances from 
baseline stool samples of healthy male participants (n = 34). High-trimethylamine-N-oxide (TMAO) 
producers in red (n = 17; those with ≥40% urinary TMAO increase from 0 min study-baseline in 
response to choline bitartrate) and low-TMAO producers in blue (n = 17; those with <40% urinary 
TMAO increase from 0 min study-baseline in response to choline bitartrate) were significantly 
different from each other (Permutational multivariate analysis of variance, PERMANOVA p = 0.01, R2 
= 0.05 with 999 permutations using the Adonis function). 
Analysis of Composition of Microbiomes (ANCOM) revealed that high-TMAO producers had 
more abundant lineages of Clostridium from Ruminococcaceae (W = 11) and Lachnospiraceae (W = 8) in 
phylum Firmicutes compared to low-TMAO producers (p < 0.05 with the strength of the ANCOM test 
indicated by W-statistic) as shown in Table 4. ANCOM tests also revealed minor differences between 
high-TMAO and low-TMAO producers (W = 1–2), whereby high-TMAO producers were represented 
by Oscillospira and Alistipes whereas low-TMAO producers represented by S24–7, Lactococcus, 
Christensenellaceae, Clostridiaceae, Bacteroidales, YS2, Catenibacterium, Gemella, Butyricicoccus and 
Ruminococcaceae. The complete percentile abundances of taxa at genus level and W-statistics for high-
TMAO versus low-TMAO producers are shown in Supplementary Table S1. 
Figure 6. Principal coordinates analysis (PCoA) plot of the unweighted UniFrac distances from baseline
stool samples of healthy m le participants (n = 34). High-trimethylamin -N-ox de (TMAO) producers
in red (n = 17; those with ≥40% urinary TMAO increase from 0 min study-baseline in response to
choline bitartrate) and low-TMAO producers in blue (n = 17; those with <40% urinary TMAO increase
from 0 min study- aseline in resp nse to choline bita trate) w re significantly different from each
other (Permutational multivariate analysis of variance, PERMANOVA p = 0.01, R2 = 0.05 with 999
permu ations using the Adonis function).
Analysis of Composition of Microbiomes (ANCOM) revealed that high-TMAO producers had more
abundant lineages of Clostridium from Ruminococcaceae (W = 11) and Lachnospiraceae (W = 8) in phylum
Firmicutes compared to l w-TMAO producers (p < 0.05 with the strength of the ANCOM test indicated
b W-statistic) as shown in Table 4. ANCOM tests also revealed minor differe ces between high-TMAO
and low-TMAO producers (W = 1–2), whereby high-TMAO producers were represented by Oscillospira
and Alistipes whereas low-TMAO producers represented by S24–7, Lactococcus, Christensenellaceae,
Clostridiaceae, Bacteroidales, YS2, Catenibacterium, Gemella, Butyricicoccus and Ruminococcaceae. The
complete percentile abundances of taxa at genus level and W-statistics for high-TMAO versus
low-TMAO producers are shown in Supplementary Table S1.
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Table 4. Analysis of Composition of Microbiomes (ANCOM) results showing percentile abundances of taxa at genus level and W-statistics for
high-trimethylamine-N-oxide (TMAO) producers (n = 17; those with ≥40% urinary TMAO increase from 0 min study-baseline in response to choline bitartrate) versus
low-TMAO producers (n = 17; those with <40% urinary TMAO increase from 0 min study-baseline in response to choline bitartrate).
High-TMAO Producers Low-TMAO Producers
Taxa 0% 25% 50% 75% 100% 0% 25% 50% 75% 100% W Reject NullHypothesis
k__Bacteria; p__Firmicutes;
c__Clostridia; o__Clostridiales;
f__Ruminococcaceae; g__Clostridium
1 1 1 78 158 1 1 1 1 1 11 TRUE
k__Bacteria; p__Firmicutes;
c__Clostridia; o__Clostridiales;
f__Lachnospiraceae; g__Clostridium
87 152 263 385 1138 1 37 96 194 340 8 TRUE
k__Bacteria; p__Bacteroidetes;
c__Bacteroidia; o__Bacteroidales;
f__S24-7; g__
1 1 1 1 5 1 1 1 49 100 2 TRUE
k__Bacteria; p__Firmicutes; c__Bacilli;
o__Lactobacillales; f__Streptococcaceae;
g__Lactococcus
1 1 1 1 1 1 1 1 1 68 2 TRUE
k__Bacteria; p__Firmicutes;
c__Clostridia; o__Clostridiales;
f__Christensenellaceae; g__
1 1 1 1 125 1 1 8 90 420 2 TRUE
k__Bacteria; p__Firmicutes;
c__Clostridia; o__Clostridiales;
f__Clostridiaceae; g__
1 1 1 1 1 1 1 1 1 67 2 TRUE
k__Bacteria; p__Bacteroidetes;
c__Bacteroidia; o__Bacteroidales;
f__; g__
1 1 1 1 9 1 1 1 1 1876 2 TRUE
k__Bacteria; p__Cyanobacteria;
c__4C0d-2; o__YS2; f__; g__ 1 1 1 1 1 1 1 1 1 126 2 TRUE
Nutrients 2020, 12, 2220 14 of 20
Table 4. Cont.
High-TMAO Producers Low-TMAO Producers
Taxa 0% 25% 50% 75% 100% 0% 25% 50% 75% 100% W Reject NullHypothesis
k__Bacteria; p__Firmicutes;
c__Erysipelotrichi;
o__Erysipelotrichales;
f__Erysipelotrichaceae;
g__Catenibacterium
1 1 1 1 1 1 1 1 1 83 2 TRUE
k__Bacteria; p__Firmicutes;
c__Clostridia; o__Clostridiales;
f__Ruminococcaceae; g__Oscillospira
1 80 143 354 1359 53 124 162 264 432 1 TRUE
k__Bacteria; p__Firmicutes; c__Bacilli;
o__Gemellales; f__Gemellaceae;
g__Gemella
1 1 1 1 5 1 1 1 1 10 1 TRUE
k__Bacteria; p__Bacteroidetes;
c__Bacteroidia; o__Bacteroidales;
f__Rikenellaceae; g__Alistipes
1 90 167 485 6008 90 150 154 233 478 1 TRUE
k__Bacteria; p__Firmicutes;
c__Clostridia; o__Clostridiales;
f__Ruminococcaceae; g__Butyricicoccus
1 1 1 56 166 1 1 36 85 175 1 TRUE
k__Bacteria; p__Firmicutes;
c__Clostridia; o__Clostridiales;
f__Ruminococcaceae; g__
1 85 254 661 1205 1 196 340 653 2396 1 TRUE
Values are abundance of reads for each percentile within the high-TMAO producer versus low-TMAO producer groups. W-statistic indicates the strength of the ANCOM test (all at
p < 0.05).
Nutrients 2020, 12, 2220 15 of 20
4. Discussion
The findings support our hypothesis that consumption of choline bitartrate, but not
phosphatidylcholine, leads to greater TMAO production and that gut microbiota composition
contributes to alterations in TMAO response to choline bitartrate. The present study design incorporated
measures of TMAO and choline metabolite absorption and excretion in conjunction with gut microbiota
composition, and thus considered together dietary and physiological factors influencing TMAO
metabolism. We demonstrate for the first time that heightened TMAO response to choline bitartrate
intake may largely be attributed to abundant lineages of Clostridium (in phylum Firmicutes) and may
provide guidance to personalized therapeutic strategies in reducing chronic disease risk.
Choline bitartrate yielded 3-times higher plasma TMAO AUC and 4.4-times higher plasma TMAO
maximum increase from baseline compared to phosphatidylcholine and no choline control, consistent
with previous studies demonstrating that excess gut microbial-generated TMA production occurred
with choline chloride [5,6]. Further, a recent study comparing choline bitartrate and krill oil containing
phosphatidylcholine and omega-3 fatty acids also showed greater TMAO production only with choline
bitartrate, but not krill oil [31]. The increase in TMAO concentration with choline bitartrate suggests
that the non-ester form without requiring an enzymatic conversion step may be a preferred substrate
for the gut microbial conversion to TMA and subsequent hepatic oxidation to TMAO. Choline bitartrate
may be readily available and utilized as indicated by circulating free choline that peaked at 1-h higher,
but the level was not sustained 2-h after consumption. The decline in plasma choline concentrations
occurred concurrently with elevated plasma TMAO from 4–6 h, indicating the time required for the
gut microbial conversion of TMA to TMAO. Higher urinary choline and TMAO excretion closely
matched plasma response, and effective urinary TMAO clearance may indicate protection against the
accumulation of TMAO.
In contrast, TMAO change from study-baseline and AUC after phosphatidylcholine consumption
did not differ compared to that of no choline control despite higher circulating and urinary free choline
concentrations. The rate of free choline availability may be a primary determinant of TMAO production
in that absorption of free choline, while rapid, is known to be saturated at 4 mM [32] leaving the excess
to reach the large intestine, whereas a delayed conversion from phosphatidylcholine to free choline may
limit large utilization of choline as a gut microbial substrate. Phosphatidylcholine consumption led to a
sustained elevation of free choline concentration throughout the 6-h study period that appears to have
entered the bloodstream at a slower rate than choline bitartrate. Given that the majority of choline in
food is in the form of phosphatidylcholine, the absence of TMAO elevation with phosphatidylcholine
counters arguments that dietary phosphatidylcholine should be avoided for TMAO-producing
characteristics. Our findings are consistent with the previous long-term egg ingestion studies showing
that the consumption of 3 eggs/day (~400 mg total choline/day) for four weeks resulted in higher plasma
choline concentration without influencing plasma TMAO concentration and scavenger receptor gene
expression compared to choline bitartrate supplementation [33]. Similarly, the consumption of two
eggs/day for four weeks resulted in higher dietary and plasma choline concentrations, and improved
markers of cardiovascular disease risk without affecting TMAO concentrations compared to an oatmeal
breakfast [34]. However, greater TMAO concentration after a single-meal egg ingestion has also been
reported [1,7]. The discrepancy may be due to phosphatidylcholine and food matrix interactions
leading to different choline kinetics and individual differences contributing to TMAO response.
An interindividual variation in urinary TMAO response to choline bitartrate consumption ranged
widely from −80% to 1400% and this difference may be attributed to the gut microbiota composition.
Consistent with our previous reports indicating that TMAO appeared to be a function of the gut
microbiota differences between individuals [9], high-TMAO producers had significantly different gut
microbiota composition compared to low-TMAO producers. Those individuals who had ≥40% increase
in TMAO response after choline bitartrate consumption (high-TMAO producers) had more lineages of
Clostridium from Ruminococcaceae and Lachnospiraceae compared to those who had <40% increase in
TMAO response (low-TMAO producers), suggesting certain microbial populations may be responsible
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for a heightened TMAO response to dietary precursor intake. Both our present and previous studies [9]
indicated that high-TMAO producers were represented by Clostridiales within the Firmicutes phylum,
with a possibility that TMAO responses differentiated at genus level depending on dietary precursor
intake and interaction with other nutrients. Moreover, our data support previous reports showing that
microbial conversion of choline to TMA is catalyzed by choline TMA-lyase that is encoded by Cut gene
clusters present in phyla Firmicutes, Proteobacteria and Actinobacteria [35]. Other minor differences in
gut microbiota composition including Oscillospira and Alistipes abundant in high-TMAO producers
and S24-7, Lactococcus, Christensenellaceae, Clostridiaceae, Bacteroidales, YS2, Catenibacterium, Gemella,
Butyricicoccus and Ruminococcaceae abundant in low-TMAO producers may be related to differences in
choline metabolism. Choline consumption by the intestinal microbiota may substantially contribute to
choline deficiency [36], which in addition to genetics and other physiologic factors may contribute to
individual differences in choline requirements. Although beta-diversity was significantly different, we
did not observe differences in alpha-diversity measures, which may have been due to the presence of
closely related features within our pool of participants.
This study was a post hoc analysis of male participants, and provided some limitations in
interpretation of the data. We explored whether differences in gut microbiota composition contributed
to differences in TMAO production, which served as a rationale for our initial focus on obesity differences.
Given a small sample size, our findings are limited to males in the normal-weight and obese BMI
categories, thus may not be generalizable to underweight and overweight individuals, women, or those
with pre-conditions of cardiovascular disease. TMAO response to choline bitartrate consumption or
variability in response did not differ between normal-weight and obese individuals (data not shown) but
a larger study may demonstrate TMAO accumulation in relation to underlying differences in metabolic
responsiveness in obesity [37,38]. The FMO3 G472A genotype was not an influential covariate, likely
due to a small sample size of the individuals with the variant allele. Factors contributing to variability
in TMAO response should be further examined, including development of a model that incorporates
obesity, gut microbiome, genotype, background diet and physiological measures. In addition, the gut
microbiome results should be interpreted with caution as differences in process, storage and exposure
to ambient air during home collection of stool may have resulted in variability, even though participants
were provided with standardized instruction and collection supplies. Another weakness of our study
is the lack of clinical endpoints including assessment of cardiovascular disease risk. The mechanism by
which TMAO may contribute to cardiovascular disease development involves enhanced cholesterol
accumulation in macrophages and foam cell formation [2,39]. No changes in high-sensitivity C-reactive
protein and oxidized low-density lipoprotein concentrations after a single meal-ingestion of eggs were
previously reported despite higher TMAO concentrations [7]. Future studies using metabolomics
and metagenomics analyses would delineate the functional relationships among choline, TMAO and
atherosclerosis including host mechanisms in tissues (adipose tissue, muscle and liver). Lastly, this
study determined an acute metabolic response and did not take into consideration adaptive changes in
gut microbiota composition nor habitual consumption of dietary precursors and potential interaction
with other nutrients. Long-term controlled feeding studies addressing the role of diet, gut microbiota
and individual characteristics in TMAO production would fully assess the utility of TMAO as a
prognostic marker for disease.
Our findings are significant on two fronts in: (1) clarifying the role of choline in TMAO metabolism
as a key first step in determining physiological consequences of TMAO on long-term health and
(2) identifying potential individual characteristics that increase propensity to TMAO accumulation
that may guide the development of therapeutic strategies through precision nutrition. Choline is an
essential bioactive micronutrient that has a critical role in biological processes including membrane
biosynthesis, cholinergic neurotransmission and methylation reactions important for downstream
gene expression and genome stability [40]. Prolonged choline deficiency is known to contribute to
fatty liver disease and cognitive decline [41]. Moreover, emerging evidence highlights that maternal
choline supplementation may improve placental function [42,43] and infant information processing
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speed [44] as well as reducing neonatal response to stress [42]. Recommendations proposing to restrict
consumption of choline as a TMAO-generating nutrient require careful consideration and balanced
reporting of dietary factors contributing to TMAO production. The development of individualized
dietary recommendations based on gut microbiota composition may be a promising means to reduce
risk of cardiovascular disease.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/8/2220/s1,
Table S1: Percentile abundances of taxa at genus level and W-statistics for high-TMAO producers (n = 17;
those with ≥40% urinary TMAO increase from 0 min study-baseline in response to choline bitartrate) versus
low-TMAO producers (n = 17; those with <40% urinary TMAO increase from 0 min study-baseline in response to
choline bitartrate).
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